SCHEMBL6922028

SCHEMBL6922028

CCCn1cnc2cc(-c3cccc(F)c3)ccc2c1=O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC2A1 P11166 1/20 0.52
RAB9A P51151 4/20 0.46
LMNA P02545 3/20 0.46
BCL2A1 Q16548 2/20 0.46
SMN1; SMN2 Q16637 4/20 0.46
NPC1 O15118 3/20 0.46
HPGD P15428 3/20 0.46
TSHR P16473 1/20 0.46
EIF4EBP1 Q13541 1/20 0.45
GRK2 P25098 1/20 0.44
GRK1 Q15835 1/20 0.44
ALDH1A1 P00352 3/20 0.44
GRM2 Q14416 1/20 0.44
TGFBR1 P36897 1/20 0.44
NFKB1 P19838 1/20 0.44
NFKB2 Q00653 1/20 0.44
RELA Q04206 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
KDM4E B2RXH2 1/20 0.43
ROCK2 O75116 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12059006 0.89 RAB9A (0.54) SLC2A1RAB9ALMNASMN1; SMN2NPC1
SCHEMBL6922988 0.85 RAB9A (0.43) SLC2A1RAB9ALMNABCL2A1SMN1; SMN2
SCHEMBL12059005 0.84 ICMT (0.47) SLC2A1RAB9ALMNABCL2A1SMN1; SMN2
SCHEMBL6922017 0.82 LMNA (0.43) SLC2A1RAB9ALMNASMN1; SMN2NPC1
SCHEMBL6920793 0.81 ICMT (0.47) SLC2A1EIF4EBP1GRK2GRK1GRM2
SCHEMBL12059116 0.79 ADRA1A (0.49) SLC2A1RAB9ALMNA
SCHEMBL6921556 0.79 LRRK2 (0.42) BCL2A1TSHRGRK2GRK1ALDH1A1
SCHEMBL6921401 0.76 PRPS1 (0.49) SLC2A1GRK2GRK1
SCHEMBL6922249 0.76 MAPT (0.46) RAB9ALMNASMN1; SMN2NPC1EIF4EBP1
SCHEMBL6921326 0.76 RAB9A (0.51) SLC2A1RAB9ALMNASMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110319380-A1 Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof SUNOVION PHARMACEUTICALS INC. (US) 2011-12-29 US disclosed
WO-2011075699-A2 COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC. (US) 2011-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110319380-A1 Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof GRM5, GRM2, GRM1 SLC2A1 357/4885RAB9A 1387/4885LMNA 4613/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.